Identification of Isavuconazole Exposure-Toxicity Threshold

Identification of Isavuconazole Exposure-Toxicity Threshold in Patients with Invasive Mold Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600126942

Enrollment

Unknown

Registered

2026-06-20

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive mold disease

Interventions

Isavuconazole TDM Cohort:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Adult patients (aged >=18 years); 2.Proven, probable, or possible invasive mold disease; 3.Scheduled to receive isavuconazole therapy with an intravenous formulation during the loading phase; 4.Agreement to undergo therapeutic drug monitoring (TDM) for isavuconazole;

Exclusion criteria

Exclusion criteria: 1.Known allergy or hypersensitivity to isavuconazole; 2.Positive pregnancy test or ongoing lactation; 3.Participation in another clinical trial within the past 3 months; 4.Receiving dialysis or extracorporeal membrane oxygenation;

Design outcomes

Primary

Measure	Time frame
Plasma Concentration of Isavuconazole;Isavuconazole Exposure-Toxicity Threshold;All-Cause Mortality;	—

Secondary

Measure	Time frame
Adverse Events;Clinical Efficacy;	—

Countries

China

Contacts

Public ContactZhang Chunhong

The First Affiliated Hospital of Wenzhou Medical University

zch760217@163.com+86 577 55579708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026